RESUMO
Regenerative medicine, encompassing various therapeutic approaches aimed at tissue repair and regeneration, has emerged as a promising field in the realm of physical therapy. Aim: This comprehensive review seeks to explore the evolving role of regenerative medicine within the domain of physical therapy, highlighting its potential applications, challenges, and current trends. Researchers selected publications of pertinent studies from 2015 to 2024 and performed an exhaustive review of electronic databases such as PubMed, Embase, and Google Scholar using the targeted keywords "regenerative medicine", "rehabilitation", "tissue repair", and "physical therapy" to screen applicable studies according to preset parameters for eligibility, then compiled key insights from the extracted data. Several regenerative medicine methods that are applied in physical therapy, in particular, stem cell therapy, platelet-rich plasma (PRP), tissue engineering, and growth factor treatments, were analyzed in this research study. The corresponding efficacy of these methods in the recovery process were also elaborated, including a discussion on facilitating tissue repair, alleviating pain, and improving functional restoration. Additionally, this review reports the challenges concerning regenerative therapies, among them the standardization of protocols, safety concerns, and ethical issues. Regenerative medicine bears considerable potential as an adjunctive therapy in physiotherapy, providing new pathways for improving tissue repair and functional results. Although significant strides have been made in interpreting the potential of regenerative techniques, further research is warranted to enhance protocols, establish safety profiles, and increase access and availability. Merging regenerative medicine into the structure of physical therapy indicates a transformative alteration in clinical practice, with the benefit of increasing patient care and improving long-term results.
Assuntos
Modalidades de Fisioterapia , Medicina Regenerativa , Humanos , Medicina Regenerativa/métodos , Medicina Regenerativa/tendências , Medicina Regenerativa/normas , Plasma Rico em Plaquetas , Doenças Musculoesqueléticas/terapia , Engenharia Tecidual/métodosRESUMO
The widespread application of mesenchymal stem cells (MSCs) in veterinary regenerative medicine highlights their promising therapeutic potential. However, the lack of standardized characterization and reporting practices across studies poses a significant challenge, compromising the assessment of their safety and efficacy. While criteria established for human MSCs serve as a foundation, the unique characteristics of animal-derived MSCs warrant updated guidelines tailored to veterinary medicine. A recent position statement outlining minimal reporting criteria for MSCs in veterinary research reflects efforts to address this need, aiming to enhance research quality and reproducibility. Standardized reporting criteria ensure transparency, facilitate evidence synthesis, and promote best practices adoption in MSC isolation, characterization, and administration. Adherence to minimal reporting criteria is crucial for maintaining scientific rigor and advancing the field of veterinary regenerative medicine. Ongoing collaboration among stakeholders is essential for effective implementation and adherence to updated guidelines, fostering excellence and innovation in MSC-based therapies for animal patients.
Assuntos
Células-Tronco Mesenquimais , Medicina Regenerativa , Animais , Medicina Regenerativa/normas , Células-Tronco Mesenquimais/citologia , Transplante de Células-Tronco Mesenquimais/veterinária , Transplante de Células-Tronco Mesenquimais/normas , Transplante de Células-Tronco Mesenquimais/métodos , Medicina Veterinária/normas , Medicina Veterinária/métodosRESUMO
Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.
Assuntos
Vesículas Extracelulares , Mesoderma , Regeneração , Medicina Regenerativa , Células-Tronco , Vesículas Extracelulares/classificação , Vesículas Extracelulares/imunologia , Vesículas Extracelulares/metabolismo , Medicina Regenerativa/métodos , Medicina Regenerativa/normas , Medicina Regenerativa/tendências , Mesoderma/citologia , Células-Tronco/citologia , Humanos , Animais , Biotecnologia/métodos , Biotecnologia/normas , Biotecnologia/tendênciasRESUMO
Hyperacute serum (HAS) is a blood derivative product that promotes the proliferation of various cell types and controls inflammation in vitro. The aim of this study is to investigate the regenerative potential of different formulations of HAS, including lyophilized and hyaluronic acid combined versions, to obtain a stable and standardized therapeutic in osteoarthritis (OA), which may be able to overcome the variability limitations of platelet-rich plasma (PRP). Primary human osteoarthritic chondrocytes were used for testing cellular viability and gene expression of OA-related genes. Moreover, a co-culture of human explants of cartilage, bone and synovium under inflammatory conditions was used for investigating the inflammatory control capacities of the different therapeutics. In this study, one formulation of lyophilized HAS achieved the high cell viability rates of liquid HAS and PRP. Gene expression analysis showed that HAS induced higher Col1a1 expression than PRP. Cytokine quantification from supernatant fluids revealed that HAS treatment of inflamed co-cultures significantly reduced levels of IL-5, IL-15, IL-2, TNFα, IL-7 and IL-12. To conclude, lyophilized HAS is a stable and standardized therapeutic with high potential in joint regeneration.
Assuntos
Condrócitos/citologia , Osteoartrite/terapia , Plasma Rico em Plaquetas/química , Regeneração , Medicina Regenerativa/normas , Soro/química , Adulto , Técnicas de Cocultura , Voluntários Saudáveis , Humanos , Pessoa de Meia-IdadeRESUMO
Over the last decade, mesenchymal stem cells (MSCs) have been considered a suitable source for cell-based therapy, especially in regenerative medicine. First, the efficacy and functions of MSCs in clinical applications have been attributed to their differentiation ability, called homing and differentiation. However, it has recently been confirmed that MSCs mostly exert their therapeutic effects through soluble paracrine bioactive factors and extracellular vesicles, especially secretome. These secreted components play critical roles in modulating immune responses, improving the survival, and increasing the regeneration of damaged tissues. The secretome content of MSCs is variable under different conditions. Oxidative stress (OS) is one of these conditions that is highly important in MSC therapy and regenerative medicine. High levels of reactive oxygen species (ROS) are produced during isolation, cell culture, and transplantation lead to OS, which induces cell death and apoptosis and limits the efficacy of their regeneration capability. In turn, the preconditioning of MSCs in OS conditions contributes to the secretion of several proteins, cytokines, growth factors, and exosomes, which can improve the antioxidant potential of MSCs against OS. This potential of MSC secretome has turned it into a new promising cell-free tissue regeneration strategy.This review provides a view of MSC secretome under OS conditions, focusing on different secretome contents of MSCs and thier possible therapeutic potential against cell therapy.
Assuntos
Células-Tronco Mesenquimais/metabolismo , Estresse Oxidativo , Secretoma , Animais , Biomarcadores , Exossomos/metabolismo , Vesículas Extracelulares/metabolismo , Humanos , Células-Tronco Mesenquimais/citologia , Espécies Reativas de Oxigênio/metabolismo , Regeneração , Medicina Regenerativa/métodos , Medicina Regenerativa/normasRESUMO
Primary progenitor cell types adequately isolated from fetal tissue samples present considerable therapeutic potential for a wide range of applications within allogeneic musculoskeletal regenerative medicine. Progenitor cells are inherently differentiated and extremely stable in standard bioprocessing conditions and can be culture-expanded to establish extensive and robust cryopreserved cell banks. Stringent processing conditions and exhaustive traceability are prerequisites for establishing a cell source admissible for further cGMP biobanking and clinical-grade production lot manufacture. Transplantation programs are ideal platforms for the establishment of primary progenitor cell sources to be used for manufacture of cell therapies or cell-based products. Well-defined and regulated procurement and processing of fetal biopsies after voluntary pregnancy interruptions ensure traceability and safety of progeny materials and therapeutic products derived therefrom. We describe herein the workflows and specifications devised under the Swiss Fetal Progenitor Cell Transplantation Program in order to traceably isolate primary progenitor cell types in vitro and to constitute Parental Cell Banks fit for subsequent industrial-scale cGMP processing. When properly devised, derived, and maintained, such cell sources established after a single organ donation can furnish sufficient progeny materials for years of development in translational musculoskeletal regenerative medicine.
Assuntos
Tecnologia Biomédica/normas , Transplante de Células/métodos , Células-Tronco Embrionárias Humanas/citologia , Cultura Primária de Células/métodos , Medicina Regenerativa/métodos , Bancos de Espécimes Biológicos/normas , Tecnologia Biomédica/métodos , Transplante de Células/normas , Células Cultivadas , Humanos , Guias de Prática Clínica como Assunto , Cultura Primária de Células/normas , Medicina Regenerativa/normas , Coleta de Tecidos e Órgãos/métodos , Coleta de Tecidos e Órgãos/normas , Obtenção de Tecidos e Órgãos/normasRESUMO
Platelet-derived products (PDPs) have gained popularity, mainly due to their high concentrations of bioactive molecules such as growth factors and cytokines, which play important roles in tissue healing and regeneration. PDPs are obtained through minimally invasive procedures and their therapeutic effect has been widely recognized. In veterinary medicine, however, the lack of standard protocols to generate PDPs is a major hurdle for assessing the clinical relevance of PDP-based therapies and for their widespread usage. The aim of this review is to analyze the technical and scientific specificities of PDPs in terms of preparation methodologies, classification categorization, nomenclature, and biological proprieties to advance their future biotechnological potential in veterinary contexts.
Assuntos
Plaquetas , Medicina Veterinária , Plaquetas/química , Citocinas/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Plasma Rico em Plaquetas/química , Padrões de Referência , Medicina Regenerativa/normas , Medicina Regenerativa/tendências , Medicina Veterinária/normas , Medicina Veterinária/tendências , CicatrizaçãoRESUMO
In the context of hematopoietic cell transplantation, hematopoietic stem/progenitor cells (HSPC) from the umbilical cord blood (UCB) present several advantages compared to adult sources including higher proliferative capacity, abundant availability and ease of collection, non-risk and painless harvesting procedure, and lower risk of graft-versus-host disease. However, the therapeutic utility of UCB HSPC has been limited to pediatric patients due to the low cell frequency per unit of UCB. The development of efficient and cost-effective strategies to generate large numbers of functional UCB HSPC ex vivo would boost all current and future medical uses of these cells. Herein, we describe a scalable serum-free co-culture system for the expansion of UCB-derived CD34+-enriched cells using microcarrier-immobilized human bone marrow-derived mesenchymal stromal cells as feeder cells.
Assuntos
Tecnologia Biomédica/normas , Células-Tronco Hematopoéticas/citologia , Células-Tronco Mesenquimais/citologia , Cultura Primária de Células/métodos , Medicina Regenerativa/normas , Tecnologia Biomédica/métodos , Células Cultivadas , Técnicas de Cocultura/métodos , Técnicas de Cocultura/normas , Humanos , Guias de Prática Clínica como Assunto , Cultura Primária de Células/normas , Medicina Regenerativa/métodosRESUMO
Non-enzymatically isolated primary dermal progenitor fibroblasts derived from fetal organ donations are ideal cell types for allogenic musculoskeletal regenerative therapeutic applications. These cell types are differentiated, highly proliferative in standard in vitro culture conditions and extremely stable throughout their defined lifespans. Technical simplicity, robustness of bioprocessing and relatively small therapeutic dose requirements enable pragmatic and efficient production of clinical progenitor fibroblast lots under cGMP standards. Herein we describe optimized and standardized monolayer culture expansion protocols using dermal progenitor fibroblasts isolated under a Fetal Transplantation Program for the establishment of GMP tiered Master, Working and End of Production cryopreserved Cell Banks. Safety, stability and quality parameters are assessed through stringent testing of progeny biological materials, in view of clinical application to human patients suffering from diverse cutaneous chronic and acute affections. These methods and approaches, coupled to adequate cell source optimization, enable the obtention of a virtually limitless source of highly consistent and safe biological therapeutic material to be used for innovative regenerative medicine applications.
Assuntos
Bancos de Espécimes Biológicos/normas , Fibroblastos/citologia , Guias de Prática Clínica como Assunto , Cultura Primária de Células/normas , Medicina Regenerativa/normas , Transplante de Células-Tronco/normas , Células Cultivadas , Derme/citologia , Humanos , Cultura Primária de Células/métodos , Medicina Regenerativa/métodos , Transplante de Células-Tronco/métodos , Preservação de Tecido/métodos , Preservação de Tecido/normas , Transplante Homólogo/métodos , Transplante Homólogo/normasRESUMO
Multiple sclerosis (MS) is the most common cause of neurological diseases. Although, there are some effective medications with regulatory approval for treating MS, they are only partially effective and cannot promote repairing of tissue damage directly which occurs in the central nervous system. Therefore, there is an essential need to develop novel therapeutic approaches for neuroprotection or repairing damaged tissue in MS. Accordingly, cell-based therapies as a novel therapeutic strategy have opened a new horizon in treatment of MS. Each setting in cell therapy has potential benefits. Human endometrial stem cells as an invaluable source for cell therapy have introduced treatment for MS. In this respect, good manufacturing practice (GMP) has a pivotal role in clinical production of stem cells. This chapter tries to describe the protocol of GMP-grade endometrial stem cells for treatment of MS.
Assuntos
Endométrio/citologia , Células-Tronco Mesenquimais/citologia , Esclerose Múltipla/terapia , Guias de Prática Clínica como Assunto , Cultura Primária de Células/métodos , Transplante de Células-Tronco/normas , Coleta de Tecidos e Órgãos/métodos , Células Cultivadas , Criopreservação/métodos , Criopreservação/normas , Feminino , Humanos , Cultura Primária de Células/normas , Medicina Regenerativa/métodos , Medicina Regenerativa/normas , Transplante de Células-Tronco/métodos , Coleta de Tecidos e Órgãos/normasRESUMO
Clinical experience gathered over two decades around therapeutic use of primary human dermal progenitor fibroblasts in burn patient populations has been at the forefront of regenerative medicine in Switzerland. Relative technical simplicity, ease of extensive serial multitiered banking, and high stability are major advantages of such cell types, assorted to ease of safety and traceability demonstration. Stringent optimization of cell source selection and standardization of biobanking protocols enables the safe and efficient harnessing of the considerable allogenic therapeutic potential yielded by primary progenitor cells. Swiss legal and regulatory requirements have led to the procurement of fetal tissues within a devised Fetal Progenitor Cell Transplantation Program in the Lausanne University Hospital. Proprietary nonenzymatic isolation of primary musculoskeletal cell types and subsequent establishment of progeny tiered cell banks under cGMP standards have enabled safe and effective management of acute and chronic cutaneous affections in various patient populations. Direct off-the-freezer seeding of viable dermal progenitor fibroblasts on a CE marked equine collagen scaffold is the current standard for delivery of the therapeutic biological materials to patients suffering from extensive and deep burns. Diversification in the clinical indications and delivery methods for these progenitor cells has produced excellent results for treatment of persistent ulcers, autograft donor site wounds, or chronic cutaneous affections such as eczema. Herein we describe the standard operating procedures for preparation and therapeutic deployment of the progenitor biological bandages within our translational musculoskeletal regenerative medicine program, as they are routinely used as adjuvants in our Burn Center to treat critically ailing patients.
Assuntos
Curativos Biológicos/normas , Células-Tronco Embrionárias Humanas/citologia , Guias de Prática Clínica como Assunto , Cultura Primária de Células/métodos , Reepitelização , Medicina Regenerativa/métodos , Preservação de Tecido/métodos , Curativos Biológicos/efeitos adversos , Queimaduras/terapia , Células Cultivadas , Humanos , Úlcera por Pressão/terapia , Cultura Primária de Células/normas , Medicina Regenerativa/normas , Ferida Cirúrgica/terapia , Preservação de Tecido/normasRESUMO
In modern biology, the correct identification of cell types is required for the developmental study of tissues and organs and the production of functional cells for cell therapies and disease modeling. For decades, cell types have been defined on the basis of morphological and physiological markers and, more recently, immunological markers and molecular properties. Recent advances in single-cell RNA sequencing have opened new doors for the characterization of cells at the individual and spatiotemporal levels on the basis of their RNA profiles, vastly transforming our understanding of cell types. The objective of this review is to survey the current progress in the field of cell-type identification, starting with the Human Cell Atlas project, which aims to sequence every cell in the human body, to molecular marker databases for individual cell types and other sources that address cell-type identification for regenerative medicine based on cell data guidelines.
Assuntos
Especificidade de Órgãos , Medicina Regenerativa/métodos , Células-Tronco/classificação , Células-Tronco/citologia , Animais , Biomarcadores , Guias como Assunto , Humanos , Especificidade de Órgãos/genética , Medicina Regenerativa/normas , Pesquisa Translacional Biomédica/métodos , Pesquisa Translacional Biomédica/normasAssuntos
Drogas em Investigação/efeitos adversos , Medicina Regenerativa/métodos , Betacoronavirus , COVID-19 , Infecções por Coronavirus/complicações , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Humanos , Pandemias , Pneumonia Viral/complicações , Medicina Regenerativa/normas , Risco , SARS-CoV-2 , Experimentação Humana Terapêutica , Estados Unidos , United States Food and Drug Administration/legislação & jurisprudênciaRESUMO
The United States Food and Drug Administration (FDA) is responsible for protecting and promoting public health through rules and regulations. Over the past few years, the field of regenerative medicine and cell therapy have garnered significant interest, and this evolving new biology is changing fast and challenging regulatory bodies. The FDA has published a series of guidance documents outlining steps to protect consumers against potentially dangerous and unproven treatments. The agency has offered a grace period for "stem cell clinics" until November 2020 to come into compliance by obtaining Investigational New Drug applications and working to secure premarket approval of their products. With the documentation of hundreds of "stem cell clinics," the FDA needs to enforce the adherence to their outlined standards to protect patients. The aim of this review was to provide an overview of these FDA regulations and some current issues within the industry. The purpose is to educate and inform the musculoskeletal community about the current government regulations of this new expanding biology. LEVEL OF EVIDENCE: Level V, expert opinion.
Assuntos
Produtos Biológicos/normas , Regulamentação Governamental , Medicina Regenerativa/legislação & jurisprudência , Medicina Regenerativa/normas , Humanos , Células-Tronco Mesenquimais , Política Pública , Terminologia como Assunto , Estados Unidos , United States Food and Drug AdministrationRESUMO
Clinical application of induced pluripotent stem cells (iPSCs), which can be differentiated into a wide variety of functional cells, is underway and some clinical trials have already been performed or are ongoing. On the other hand, the risk of carcinogenesis is an issue and the mechanism of cellular reprograming remains unknown. When iPSCs and differentiated cells are used for medical applications, quality control is also important. Here we discuss the possibility of performing quality control of iPSCs by evaluation of phospholipids, which are not just structural components of lipid bilayer membranes, but also have multiple physiological functions. Recently, methods for analysis of lipids have become more widely available and easier to perform. This article reviews the role of iPSCs in regenerative medicine and examines the possibility of using phospholipids for quality control of iPSCs and differentiated cells.
Assuntos
Células-Tronco Pluripotentes Induzidas/citologia , Lipídeos/análise , Controle de Qualidade , Medicina Regenerativa/normas , Diferenciação Celular , HumanosRESUMO
Decellularised tissues and organs have been successfully used in a variety of tissue engineering/regenerative medicine applications. Because of the complexity of each tissue (size, porosity, extracellular matrix (ECM) composition etc.), there is no standardised protocol and the decellularisation methods vary widely, thus leading to heterogeneous outcomes. Physical, chemical, and enzymatic methods have been developed and optimised for each specific application and this review describes the most common strategies utilised to achieve decellularisation of soft and hard tissues. While removal of the DNA is the primary goal of decellularisation, it is generally achieved at the expense of ECM preservation due to the harsh chemical or enzymatic processing conditions. As denaturation of the native ECM has been associated with undesired host responses, decellularisation conditions aimed at effectively achieving simultaneous DNA removal and minimal ECM damage will be highlighted. Additionally, the utilisation of decellularised matrices in regenerative medicine is explored, as are the most recent strategies implemented to circumvent challenges in this field. In summary, this review focusses on the latest advancements and future perspectives in the utilisation of natural ECM for the decoration of synthetic porous scaffolds.
Assuntos
Regeneração Óssea/genética , Matriz Extracelular/química , Engenharia Tecidual , Alicerces Teciduais/química , Animais , Materiais Biocompatíveis/química , Materiais Biocompatíveis/farmacologia , DNA/efeitos dos fármacos , Matriz Extracelular/transplante , Humanos , Ligamentos/efeitos dos fármacos , Ligamentos/crescimento & desenvolvimento , Medicina Regenerativa/normas , Tendões/efeitos dos fármacos , Tendões/crescimento & desenvolvimento , Alicerces Teciduais/normasRESUMO
Cell and gene therapy products are rapidly being integrated into mainstream medicine. Developing global capability will facilitate broad access to these novel therapeutics. An initial step toward achieving this goal is to understand cell and gene therapy manufacturing capability in each region. We conducted an academic survey in 2018 to assess cell and gene therapy manufacturing capacity in Australia and New Zealand. We examined the following: the number and types of cell therapy manufacturing facilities; the number of projects, parallel processes and clinical trials; the types of products; and the manufacturing and quality staffing levels. It was found that Australia and New Zealand provide diverse facilities for cell therapy manufacturing, infrastructure and capability. Further investment and development will enable both countries to make important decisions to meet the growing need for cell and gene therapy and regenerative medicine in the region.
Assuntos
Terapia Baseada em Transplante de Células e Tecidos , Terapia Genética , Instalações Industriais e de Manufatura/provisão & distribuição , Austrália , Terapia Baseada em Transplante de Células e Tecidos/métodos , Terapia Baseada em Transplante de Células e Tecidos/normas , Terapia Baseada em Transplante de Células e Tecidos/estatística & dados numéricos , Ensaios Clínicos como Assunto/métodos , Ensaios Clínicos como Assunto/estatística & dados numéricos , Terapia Genética/legislação & jurisprudência , Terapia Genética/métodos , Terapia Genética/normas , Terapia Genética/estatística & dados numéricos , Regulamentação Governamental , Financiamento da Assistência à Saúde , Humanos , Instalações Industriais e de Manufatura/legislação & jurisprudência , Instalações Industriais e de Manufatura/organização & administração , Instalações Industriais e de Manufatura/estatística & dados numéricos , Nova Zelândia , Medicina Regenerativa/legislação & jurisprudência , Medicina Regenerativa/normas , Medicina Regenerativa/estatística & dados numéricosRESUMO
Cell therapy approaches dedicated to the treatment of dystrophinopathies and involving essentially myoblasts and mesoangioblasts have produced mitigated clinical results. If several types of alternative progenitors have been developed, no standardized comparison has been carried out yet to investigate their regenerative efficacy in vivo, at least at a local level. A comparative study has therefore been designed recently aiming at giving a new impetus to this therapeutic field.
TITLE: Thérapie cellulaire des maladies musculaires - Un avenir à l'aune d'une comparaison des progéniteurs. ABSTRACT: Les approches de thérapie cellulaire des dystrophinopathies basées sur l'utilisation de myoblastes ou de mésoangioblastes se sont traduites par des résultats cliniques mitigés. De nombreux candidats cellulaires alternatifs ont été décrits, mais aucune comparaison standardisée n'a pu encore établir leurs efficacités, ne serait-ce qu'en vue d'une régénération musculaire localisée. Une étude comparative a donc été décidée récemment et pourrait permettre de donner un nouvel élan à cette approche.